Trinity Innovation Fund
Trinity Innovation Fund is a venture capital firm based in Beijing, China, specializing in early and growth-stage investments. Established in 2011, the firm focuses on transforming achievements in science and technology, particularly in the medical and health-related sectors, including pharmaceuticals, biotechnology, and high-end medical devices. In 2019, it launched the Trinity Zhongzhi RMB Fund, furthering its commitment to investing in innovative companies within China. With a strategic emphasis on biotechnology and drug discovery, Trinity Innovation Fund aims to support advancements that can lead to significant improvements in healthcare and medical technology.
Xingshen Zhineng is a supplier of smart logistics products and a provider of unmanned driving core technology. It has full-stack independent research and development and design capabilities ranging from chassis, structure, hardware, and software to unmanned driving technology and solutions. Xingshen Intelligent has independently developed the Chaoying, Fanyu, Benxiao, Jedi, and Buyi series of unmanned vehicle products based on independent and controllable software and hardware technologies. The company has introduced a line of unmanned vehicle products suitable for a variety of terminal logistics application scenarios, as well as unmanned driving kits for automatic driving models such as sweepers, inspection vehicles, and unmanned buses.
Epigenic Therapeutics is a biotech firm that offers gene editing therapy.
Aijie Boya is a medical instrument and magnetic solid-phase material company.
Bluepha integrates bioengineering and data science to design, develop, and commercialize bio-based products that deliver value to a board range of industries, including consumer goods, healthcare, specialty chemicals, agriculture, electronics and more.
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.
Bluepha integrates bioengineering and data science to design, develop, and commercialize bio-based products that deliver value to a board range of industries, including consumer goods, healthcare, specialty chemicals, agriculture, electronics and more.
XW Laboratories is an Asia-Pacific biopharmaceutical company dedicated to discovering and developing transformational medicines that will markedly improve the quality of life in patients suffering from neurological disorders. Founded in 2014, XW Laboratories has developed 3 unique drug R&D platforms that not only allow us to improve upon existing medication through approaches such as prodrug and functional group switch, but also be at the forefront of medicinal technology in immunoneurology through the application of their mitochondria-targeting platform.
Dizal Pharmaceutical is a research-based biotechnology company dedicated to the discovery, development, and commercialization of first-in-class/best-in-class medicines.
Bluepha integrates bioengineering and data science to design, develop, and commercialize bio-based products that deliver value to a board range of industries, including consumer goods, healthcare, specialty chemicals, agriculture, electronics and more.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.